Evidence map›Paper›PMID 37920468›Full record

ArticleFrontiers in immunology2023

The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.

Déborah Lécuyer, Roberta Nardacci, Désirée Tannous, Emie Gutierrez-Mateyron, Aurélia Deva Nathan, Frédéric Subra, Cristina Di Primio, Paola Quaranta, Vanessa Petit, Clémence Richetta and 21 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 9 institutions in 2 countries.

Déborah LécuyerUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Roberta NardacciNational Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
Désirée TannousUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Emie Gutierrez-MateyronUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Aurélia Deva NathanUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Frédéric SubraUniversité Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.
Cristina Di PrimioInstitute of Neuroscience, Italian National Research Council, Pisa, Italy.
Paola QuarantaInstitute of Neuroscience, Italian National Research Council, Pisa, Italy.
Vanessa PetitUniversité Paris-Saclay, Inserm U1274, CEA, Genetic Stability, Stem Cells and Radiation, Fontenay-aux-Roses, France.
Clémence RichettaUniversité Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.
Ali Mostefa-KaraUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Franca Del NonnoNational Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
Laura FalascaNational Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
Romain MarlinUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA- HB/IDMIT), Fontenay-aux-Roses, France.
Pauline MaisonnasseUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA- HB/IDMIT), Fontenay-aux-Roses, France.
Julia DelahousseUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Juliette PascaudUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA- HB/IDMIT), Fontenay-aux-Roses, France.
Eric DeprezUniversité Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.
Marie NaigeonGustave Roussy Cancer Center, Villejuif, France.
Nathalie ChaputUniversité Paris-Saclay, Inserm, CNRS, Analyse Moléculaire, Modélisation et Imagerie de la Maladie Cancéreuse, Laboratoire d'Immunomonitoring en Oncologie, Villejuif, France.
Angelo PaciUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Véronique SaadaDepartment of Biology and Pathology, Gustave Roussy Cancer Center, Villejuif, France.
David GhezUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Xavier MarietteUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA- HB/IDMIT), Fontenay-aux-Roses, France.
Mario CostaInstitute of Neuroscience, Italian National Research Council, Pisa, Italy.
Mauro PistelloRetrovirus Center, Department of Translational Research, Universita of Pisa, Pisa, Italy.
Awatef AllouchUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Olivier DelelisUniversité Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.
Mauro PiacentiniNational Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA- HB/IDMIT), Fontenay-aux-Roses, France.
Jean-Luc PerfettiniUniversité Paris-Saclay, Inserm UMR1030, Laboratory of Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France.
Université Paris-Saclay · FRInstitut Gustave Roussy · FRInserm · FRIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITCentre National de la Recherche Scientifique · FRNational Research Council · ITUniversity of Pisa · ITAssistance Publique – Hôpitaux de Paris · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here, we report that the purinergic receptor P2X7 and NLRP3 inflammasome are cellular host factors required for SARS-CoV-2 infection. Lung autopsies from patients with severe coronavirus disease 2019 (COVID-19) reveal that NLRP3 expression is increased in host cellular targets of SARS-CoV-2 including alveolar macrophages, type II pneumocytes and syncytia arising from the fusion of infected macrophages, thus suggesting a potential role of NLRP3 and associated signaling pathways to both inflammation and viral replication.

Indexed as

COVID-19InflammasomesCOVID-19 Drug TreatmentHumansInflammationNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsReceptors, PurinergicSARS-CoV-2InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsReceptors, PurinergicCOVID-19inflammasomeNLRP3P2X7SARS-CoV-2

Identifiers

PMID37920468
PMCPMC10619763
OpenAlexW4387742468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.